The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Open accessAbstract
OBJECTIVES: The objectives were to describe Surveillance, Epidemiology and End Results (SEER) hepatocellular carcinoma (HCC) incidence trends and the US liver cancer mortality trends by geography, age, race/ethnicity, and gender. METHODS: HCC incidence data from SEER 18 registries and liver cancer mortality data from the National Center for Health Statistics were analyzed. Rates and joinpoint trends were calculated by demographic subgroup. State-level liver cancer mortality rates and trends were mapped. RESULTS: HCC incidence rates in SEER registries did not significantly increase during 2007-2010; however, the US liver cancer mortality rates did increase. HCC incidence and liver cancer mortality rates increased among black, Hispanic, and white men aged 50+ years and decreased among 35-49-year-old men in all racial/ethnic groups including Asians/Pacific Islanders. Significantly increasing incidence and mortality rates among women were restricted to blacks, Hispanics, and whites aged 50+ years. Asian/Pacific Islander liver cancer mortality rates decreased during 2000-2010 with decreasing rates among women aged 50-64 years and men aged 35-49 years and stable rates in other groups. During 2006-2010, among individuals 50-64 years of age, blacks and Hispanics had higher incidence and mortality rates than Asians/Pacific Islanders. Liver cancer mortality rates were highest in Louisiana, Mississippi, Texas, and Washington, DC. CONCLUSIONS: Decreasing HCC incidence and liver cancer mortality rates among Asians/Pacific Islanders, men aged 35-49 years, and the nonsignificant increase in overall HCC incidence rates suggest that the peak of the epidemic may be near or have passed. Findings of geographic variation in mortality rates can inform control efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“Other HCC risk factors include chronic hepatitis B virus (HBV) infection (18), obesity (19), diabetes (20), non-alcoholic fatty liver disease (NAFLD) (21), and excessive alcohol use (22), all of which occur at variable frequencies across socio-demographic sectors of the population (23–27).”
BackgroundPermutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Cited by
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Self-citationMortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Tapper, E. B., & Parikh, N. D. (2018) · BMJ · doi:10.1136/bmj.k2817 · Cited by 856
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
“Hepatocellular carcinoma (HCC), a leading worldwide cause of cancer-related morbidity and mortality, frequently presents as incurable liver-limited or widespread metastatic disease (1, 2).”
BackgroundGong, N., Ma, X., Ye, X., Zhou, Q., Chen, X., Tan, X., Yao, S., Huo, S., Zhang, T., Chen, S., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0373-6 · Cited by 601
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., & Sirlin, C. B. (2018) · Abdominal Radiology · doi:10.1007/s00261-017-1209-1 · Cited by 480
Beste, L. A., Leipertz, S. L., Green, P. K., Dominitz, J. A., Ross, D., & Ioannou, G. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.056 · Cited by 459
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7412 · Cited by 442
Self-citationTumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 426
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012
White, D. L., Thrift, A. P., Kanwal, F., Davila, J., & El-Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.020 · Cited by 418
Torre, L. A., Sauer, A. M. G., Chen, M. S., Kagawa‐Singer, M., Jemal, A., & Siegel, R. L. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21335 · Cited by 393
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
The evolving epidemiology of hepatocellular carcinoma: a global perspective
Wallace, M. C., Preen, D., Jeffrey, G. P., & Adams, L. A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1028363 · Cited by 374
The changing epidemiology of liver diseases in the Asia–Pacific region
Wong, M. C. S., Huang, J. L. W., George, J., Huang, J., Leung, C., Eslam, M., Chan, H. L. Y., & Ng, S. C. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0055-0 · Cited by 344
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Sayiner, M., Golabi, P., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05537-2 · Cited by 339
Nath, A., Li, I., Roberts, L. R., & Chan, C. (2015) · Scientific Reports · doi:10.1038/srep14752 · Cited by 338
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
Self-citationDownstaging hepatocellular carcinoma: A systematic review and pooled analysis
Parikh, N. D., Waljee, A. K., & Singal, A. G. (2015) · Liver Transplantation · doi:10.1002/lt.24169 · Cited by 273
Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review
Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00067 · Cited by 262
Bogumil, D., Park, S., Le Marchand, L., Haiman, C. A., Wilkens, L. R., Boushey, C. J., & Setiawan, V. W. (2019) · Hepatology Communications · doi:10.1002/hep4.1313 · Cited by 52
“Given there is considerable variation in HCC incidence and CLD mortality by race/ethnicity,(3,10-13) there is a need to identify possible sources for this variation in risk.”
BackgroundAdult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease
Ambade, A., Satishchandran, A., Gyongyosi, B., Lowe, P., & Szabo, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i16.4091 · Cited by 52
Chak, E., Taefi, A., Li, C.-S., Chen, M. S., Harris, A. M., MacDonald, S., & Bowlus, C. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0448 · Cited by 28
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Alcoholic Liver Disease Accelerates Early Hepatocellular Cancer in a Mouse Model
Szabo, G. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-98788-0_5 · Cited by 4
Metadata
- Authors
- Altekruse, S. F., Henley, J. S., Cucinelli, J. E., & McGlynn, K. A.
- Venue
- American Journal of Gastroenterology
- Published
- 2014-04
- Volume
- 109
- Issue
- 4
- Pages
- 542-553
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2026697625
- Cited by
- 429
- References
- 25
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.